9.18MMarket Cap-200P/E (TTM)
0.241High0.228Low219.42KVolume0.230Open0.231Pre Close51.44KTurnover0.89%Turnover RatioLossP/E (Static)39.42MShares1.31052wk High-3.28P/B5.77MFloat Cap0.20252wk Low--Dividend TTM24.78MShs Float9324.000Historical High--Div YieldTTM5.75%Amplitude0.202Historical Low0.234Avg Price1Lot Size
Viracta Therapeutics Stock Forum
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company, recently shared positive data from the Phase 2 NAVAL-1 trial, which focuses on relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL). This article aims to provide a comprehensive overvi...
Benzinga· 7 mins ago
here are 6 cancer readouts to watch this quarter:
$ImmunityBio (IBRX.US)$ : Anktiva ▻ PDUFA ▻ Bladder CA
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib ▻ PDUFA ▻ Glioma
$GlycoMimetics (GLYC.US)$ : Uproleselan ▻ Ph3 ▻ AML
$FibroGen (FGEN.US)$ : Pamrevlumab ▻ Ph3 ▻ Pancreatic CA
$Viracta Therapeutics (VIRX.US)$ : Nana-val ▻ Ph3 ▻ Lymphoma
No comment yet